Vampire-inspired blood thinner begins new round of trials

Oct 29, 2010

(PhysOrg.com) -- Just in time for Halloween, University of Wisconsin School of Medicine and Public Health physicians have begun testing an experimental blood thinner that mimics a chemical in vampire-bat saliva.

The UW Health Comprehensive Stroke Center is one of 32 locations worldwide taking part in a new stage 3 clinical trial of desmoteplase, a genetically engineered drug aimed at treating stroke.

It is based on an enzyme that vampire bats secrete to thin the blood of their victims and keep it from clotting as the bats feed. Its name comes from the Latin name for , Desmodus Rotundus.

The University of Wisconsin recently enrolled its first patient in the Efficacy and Safety Study of Desmoteplase to Treat (DIAS-4) Study, says Dr. Matthew Jensen, a UW Health stroke neurologist, who heads the UW branch of the trial. The study is being done at UW Hospital and Clinics.

The drug can extend the window of medical treatment for stroke patients up to nine hours after stroke onset. The current gold standard for stroke treatment, rTPA, can only be given for up to four and one-half hours, because after that it has not been shown to be effective, and it can cause bleeding in the brain.

Desmoteplase may be safer, and stroke specialists have been waiting for a drug to help those who arrive at the hospital too late for the conventional clot-busting medicine.

Jensen notes that the UW stroke team takes calls from around the state from doctors who are looking for help for patients who arrive too late for standard treatment. This trial offers additional options for some of those people.

Results from earlier trials have been mixed, so it is hoped that DIAS 4 will settle the question of which patients can most benefit from the drug, says Jensen.

In an , a blood clot blocks circulation to part of the brain, and after some hours without oxygenated blood, the affected begins to die. But Jensen explains that some patients have enough collateral circulation via minor blood vessels that their injured brain remains salvageable for longer.

Physicians at UW Hospital will use MRI (magnetic resonance imaging) and CT angiograms to find patients who are better candidates.

Explore further: Neutralising antibodies for safer organ transplants

add to favorites email to friend print save as pdf

Related Stories

Study opens way for later treatment of acute stroke

Sep 15, 2008

The time span in which treatment should be given for acute ischaemic stroke – i.e. stroke caused by a clot or other obstruction to the blood supply – can be lengthened. This according to a study from the Swedish medical ...

Leukemia drug could save lives of stroke patients

Jun 22, 2008

[B]Studies in mice reveal why tPA may cause brain damage[/B] The drug tPA is the most effective treatment currently available for stroke patients, but its safety is limited to use within the first three hours following the ...

Recommended for you

Neutralising antibodies for safer organ transplants

14 hours ago

Serious complications can arise following kidney transplants. If dialysis is required within the first seven days, then the transplanted organ is said to have a Delayed Graft Function (DGF), and essentially ...

User comments : 0